T. Rowe Price Associates’s MediciNova MNOV Stock Holding History

T. Rowe Price Associates’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20,700	Closed	-$44K	–	3038
2024 Q3	$44K	Hold	20,700	–	–	﹤0.01%	2944
2024 Q2	$30K	Hold	20,700	–	–	﹤0.01%	2895
2024 Q1	$31K	Hold	20,700	–	–	﹤0.01%	2911
2023 Q4	$32K	Hold	20,700	–	–	﹤0.01%	2850
2023 Q3	$44K	Hold	20,700	–	–	﹤0.01%	2791
2023 Q2	$48K	Hold	20,700	–	–	﹤0.01%	2807
2023 Q1	$45K	Hold	20,700	–	–	﹤0.01%	2804
2022 Q4	$42K	Hold	20,700	–	–	﹤0.01%	2832
2022 Q3	$45K	Sell	20,700 -22,400	-52%	-$51.9K	﹤0.01%	2852
2022 Q2	$109K	Hold	43,100	–	–	﹤0.01%	2743
2022 Q1	$115K	Buy	43,100 +11,600	+37%	+$28.4K	﹤0.01%	2826
2021 Q4	$84K	Hold	31,500	–	–	﹤0.01%	2892
2021 Q3	$119K	Hold	31,500	–	–	﹤0.01%	2814
2021 Q2	$134K	Sell	31,500 -3,087	-9%	-$13.3K	﹤0.01%	2799
2021 Q1	$175K	Buy	+34,587	New	+$201K	﹤0.01%	2719

Other funds holding MNOV

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's MNOV Position: Q4 2024 in Review

T. Rowe Price Associates sold out of MediciNova (MNOV) in Q4 2024, closing a stake of 20,700 shares — an estimated $44K sold.

T. Rowe Price Associates first reported a position in MNOV in Q1 2021 and held it in 15 quarters. The position peaked at $175K in Q1 2021. 30 funds tracked by Wall St. Rank hold MNOV as of Q4 2024.

T. Rowe Price Associates reported no remaining MediciNova position as of Q4 2024 after selling out during the quarter.
T. Rowe Price Associates sold 20,700 MediciNova shares in Q4 2024, an estimated $44K.
T. Rowe Price Associates first reported a position in MediciNova in Q1 2021 and held it in 15 quarters.
T. Rowe Price Associates's MediciNova position peaked at $175K in Q1 2021.
30 funds tracked by Wall St. Rank held MediciNova as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.